Head to Head Contrast: Unicycive Therapeutics (NASDAQ:UNCY) versus Arvinas (NASDAQ:ARVN)

Unicycive Therapeutics (NASDAQ:UNCY) and Arvinas (NASDAQ:ARVN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Unicycive Therapeutics and Arvinas, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	0	0	4	1	3.20
Arvinas	0	1	14	0	2.93

Unicycive Therapeutics presently has a consensus target price of $5.13, indicating a potential upside of 653.68%. Arvinas has a consensus target price of $63.50, indicating a potential upside of 243.61%. Given Unicycive Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Unicycive Therapeutics is more favorable than Arvinas.

Institutional and Insider Ownership

40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 95.2% of Arvinas shares are owned by institutional investors. 24.1% of Unicycive Therapeutics shares are owned by company insiders. Comparatively, 5.2% of Arvinas shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Unicycive Therapeutics has a beta of 2.36, indicating that its share price is 136% more volatile than the S&P 500. Comparatively, Arvinas has a beta of 1.82, indicating that its share price is 82% more volatile than the S&P 500.

Profitability

This table compares Unicycive Therapeutics and Arvinas’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	N/A	-29.88%
Arvinas	N/A	-50.26%	-24.87%

Earnings & Valuation

This table compares Unicycive Therapeutics and Arvinas”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680,000.00	103.80	-$30.54 million	($0.97)	-0.70
Arvinas	$161.10 million	7.88	-$367.30 million	($4.67)	-3.96

Unicycive Therapeutics has higher earnings, but lower revenue than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Unicycive Therapeutics beats Arvinas on 10 of the 14 factors compared between the two stocks.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

About Arvinas

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.